Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

Eli Lilly shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion.

Eli Lilly stock recently achieved a significant milestone, reaching a 52-week high of $935.68, with shares now trading at $935.97. This marks a notable achievement for the pharmaceutical giant, reflecting a strong performance over the past year.

Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli Lilly recently announced a significant partnership with Walmart to sell its popular weight-loss drug, Zepbound, at a discounted retail price through Walmart pharmacies.

Eli Lilly has a leading position in a hot new drug category, but there's one notable problem to consider.

Eli Lilly & Company (NYSE:LLY) continues to stand out as a significant player in the pharmaceutical sector, particularly recognized for its robust earnings growth projections over the next five years.

Now, let’s talk about the real contenders, okay. Let’s start with Eli Lilly, one I always said was going to get to trillion dollars, but it’s really stumbled here. It’s in fourth.

With a market cap of around $730 billion, Eli Lilly ( LLY 0.92%) is one of the largest pharmaceutical companies on planet Earth. It has a strong position in the emerging niche of weight loss drugs, with patent protections that extend into the mid-2030s. And there's a solid pipeline of drugs coming up, too.

Shares of Eli Lilly LLY have surged 16% in the past week, driven primarily by positive investor expectations around the broader pharmaceutical sector after Pfizer PFE announced a landmark agreement with the Trump administration. Through its deal, Pfizer ...

While the pharma giant Eli Lilly has lagged behind the broader market over the past year, it has outpaced the health care space, and analysts remain strongly bullish on the stock’s prospects.